Oncology-Cancer Drugs Market By Drug Class (Chemotherapy, Targeted Therapy, Immunotherapy , Hormonal Therapy), By Indication : Global Opportunity Analysis and Industry Forecast, 2024-2033

Description

The global oncology-cancer drugs market was valued at $167.0 billion in 2023, and is projected to reach $335.2 billion by 2033, growing at a CAGR of 7.2% from 2024 to 2033.

The oncology/cancer drugs encompass pharmaceuticals specifically designed to diagnose, treat, and manage various types of cancer. These drugs target cancerous cells or interfere with processes involved in cancer growth and spread. It includes a wide array of therapeutic approaches, ranging from traditional chemotherapy to more targeted therapies like immunotherapy and precision medicine.

The global oncology-cancer drugs market is driven by rise in incidence of cancer globally due to aging population, lifestyle changes, and environmental exposures, which drives the demand for innovative therapies. This growing patient population highlights the need for continuous R&D efforts to address diverse cancer types and unmet medical needs. Furthermore, progress in the field of science and technology, specifically in disciplines such as molecular biology, genomics, and immunotherapy, are propelling substantial advancements in the development of cancer drugs. The rise of precision medicine strategies, which focus on specific molecular abnormalities that fuel cancer progression, is becoming increasingly prominent. This has resulted in the creation of more potent and less harmful therapies, fueling growth in the oncology drugs market.

However, high development costs of oncology drugs are extensive and costly, often requiring significant investments in preclinical studies, clinical trials, and regulatory approvals which limit the adoption of cancer drugs. Nevertheless, approval from regulatory authorities associated with new treatments and drugs is expected to create several opportunities for the market players. For instance, in October 2023, the U.S. Food and Drug Administration (FDA) approved several new treatments for a range of cancers over the summer. In July, the FDA approved a new indication for Jemperli (dostarlimab) in endometrial cancer.

Segmentation Overview

The oncology-cancer drugs market is segmented into drug class type, indication, and region. Depending on drug class type, the market is categorized into chemotherapy, targeted therapy, immunotherapy (biologic therapy), and hormonal therapy. According to indication, it is divided into lung cancer, stomach cancer, colorectal cancer, breast cancer, prostate cancer, liver cancer, esophagus cancer, cervical cancer, kidney cancer, bladder cancer, and other cancers. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

Depending on drug class type, the targeted therapy segment held the largest market share in 2023.

By indication, the breast cancer segment accounted for the highest share in the market in 2023.

Region wise, North America dominated the oncology-cancer drugs market in 2023.

Competitive Scenario

The major players operating in the oncology/cancer drugs market include AbbVie Inc., Amgen, Astellas Pharma Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Johnson & Johnson, Merck & Co., Inc., Novartis AG, and Pfizer Inc. Other players in oncology/cancer drugs market includes Bayer AG, Regeneron Pharmaceuticals Inc., and Eli Lilly and Company. These players have adopted several strategies, including partnerships, collaborations, and R&D to maintain their position in the competitive market.

Additional benefits you will get with this purchase are:

Quarterly Update and* (only available with a corporate license, on listed price)
5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
Free Upcoming Version on the Purchase of Five and Enterprise User License.
16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
Free data Pack on the Five and Enterprise User License. (Excel version of the report)
Free Updated report if the report is 6-12 months old or older.
24-hour priority response*
Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

Regulatory Guidelines
Additional company profiles with specific to client's interest
Additional country or region analysis- market size and forecast
Expanded list for Company Profiles
Historic market data
Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Drug Class

Chemotherapy
Targeted Therapy
Immunotherapy (Biologic Therapy)
Hormonal Therapy

By Indication

Lung Cancer
Stomach Cancer
Colorectal Cancer
Breast Cancer
Prostate Cancer
Liver Cancer
Esophagus Cancer
Cervical Cancer
Kidney Cancer
Bladder Cancer
Other Cancers

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- South Africa
- Saudi Arabia
- Rest of LAMEA

Key Market Players:

AbbVie Inc.
Amgen
Astellas Pharma Inc.
AstraZeneca plc
Bristol-Myers Squibb Company
F. Hoffmann-La Roche Ltd.
Johnson & Johnson
Merck & Co., Inc.
Novartis AG
Pfizer Inc.

Product Code: A00042

CHAPTER 1: INTRODUCTION

1.1. Report Description
1.2. Key Market Segments
1.3. Key Benefits
1.4. Research Methodology
- 1.4.1. Primary Research
- 1.4.2. Secondary Research
- 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

3.1. Market Definition and Scope
3.2. Key Findings
- 3.2.1. Top Investment Pockets
- 3.2.2. Top Winning Strategies
3.3. Porter's Five Forces Analysis
- 3.3.1. Bargaining Power of Suppliers
- 3.3.2. Threat of New Entrants
- 3.3.3. Threat of Substitutes
- 3.3.4. Competitive Rivalry
- 3.3.5. Bargaining Power among Buyers
3.4. Market Dynamics
- 3.4.1. Drivers
- 3.4.2. Restraints
- 3.4.3. Opportunities

CHAPTER 4: ONCOLOGY-CANCER DRUGS MARKET, BY DRUG CLASS

4.1. Market Overview
- 4.1.1 Market Size and Forecast, By Drug Class
4.2. Chemotherapy
- 4.2.1. Key Market Trends, Growth Factors and Opportunities
- 4.2.2. Market Size and Forecast, By Region
- 4.2.3. Market Share Analysis, By Country
4.3. Targeted Therapy
- 4.3.1. Key Market Trends, Growth Factors and Opportunities
- 4.3.2. Market Size and Forecast, By Region
- 4.3.3. Market Share Analysis, By Country
4.4. Immunotherapy (Biologic Therapy)
- 4.4.1. Key Market Trends, Growth Factors and Opportunities
- 4.4.2. Market Size and Forecast, By Region
- 4.4.3. Market Share Analysis, By Country
4.5. Hormonal Therapy
- 4.5.1. Key Market Trends, Growth Factors and Opportunities
- 4.5.2. Market Size and Forecast, By Region
- 4.5.3. Market Share Analysis, By Country

CHAPTER 5: ONCOLOGY-CANCER DRUGS MARKET, BY INDICATION

5.1. Market Overview
- 5.1.1 Market Size and Forecast, By Indication
5.2. Lung Cancer
- 5.2.1. Key Market Trends, Growth Factors and Opportunities
- 5.2.2. Market Size and Forecast, By Region
- 5.2.3. Market Share Analysis, By Country
5.3. Stomach Cancer
- 5.3.1. Key Market Trends, Growth Factors and Opportunities
- 5.3.2. Market Size and Forecast, By Region
- 5.3.3. Market Share Analysis, By Country
5.4. Colorectal Cancer
- 5.4.1. Key Market Trends, Growth Factors and Opportunities
- 5.4.2. Market Size and Forecast, By Region
- 5.4.3. Market Share Analysis, By Country
5.5. Breast Cancer
- 5.5.1. Key Market Trends, Growth Factors and Opportunities
- 5.5.2. Market Size and Forecast, By Region
- 5.5.3. Market Share Analysis, By Country
5.6. Prostate Cancer
- 5.6.1. Key Market Trends, Growth Factors and Opportunities
- 5.6.2. Market Size and Forecast, By Region
- 5.6.3. Market Share Analysis, By Country
5.7. Liver Cancer
- 5.7.1. Key Market Trends, Growth Factors and Opportunities
- 5.7.2. Market Size and Forecast, By Region
- 5.7.3. Market Share Analysis, By Country
5.8. Esophagus Cancer
- 5.8.1. Key Market Trends, Growth Factors and Opportunities
- 5.8.2. Market Size and Forecast, By Region
- 5.8.3. Market Share Analysis, By Country
5.9. Cervical Cancer
- 5.9.1. Key Market Trends, Growth Factors and Opportunities
- 5.9.2. Market Size and Forecast, By Region
- 5.9.3. Market Share Analysis, By Country
5.10. Kidney Cancer
- 5.10.1. Key Market Trends, Growth Factors and Opportunities
- 5.10.2. Market Size and Forecast, By Region
- 5.10.3. Market Share Analysis, By Country
5.11. Bladder Cancer
- 5.11.1. Key Market Trends, Growth Factors and Opportunities
- 5.11.2. Market Size and Forecast, By Region
- 5.11.3. Market Share Analysis, By Country
5.12. Other Cancers
- 5.12.1. Key Market Trends, Growth Factors and Opportunities
- 5.12.2. Market Size and Forecast, By Region
- 5.12.3. Market Share Analysis, By Country

CHAPTER 6: ONCOLOGY-CANCER DRUGS MARKET, BY REGION

6.1. Market Overview
- 6.1.1 Market Size and Forecast, By Region
6.2. North America
- 6.2.1. Key Market Trends and Opportunities
- 6.2.2. Market Size and Forecast, By Drug Class
- 6.2.3. Market Size and Forecast, By Indication
- 6.2.4. Market Size and Forecast, By Country
- 6.2.5. U.S. Oncology-Cancer Drugs Market
  - 6.2.5.1. Market Size and Forecast, By Drug Class
  - 6.2.5.2. Market Size and Forecast, By Indication
- 6.2.6. Canada Oncology-Cancer Drugs Market
  - 6.2.6.1. Market Size and Forecast, By Drug Class
  - 6.2.6.2. Market Size and Forecast, By Indication
- 6.2.7. Mexico Oncology-Cancer Drugs Market
  - 6.2.7.1. Market Size and Forecast, By Drug Class
  - 6.2.7.2. Market Size and Forecast, By Indication
6.3. Europe
- 6.3.1. Key Market Trends and Opportunities
- 6.3.2. Market Size and Forecast, By Drug Class
- 6.3.3. Market Size and Forecast, By Indication
- 6.3.4. Market Size and Forecast, By Country
- 6.3.5. Germany Oncology-Cancer Drugs Market
  - 6.3.5.1. Market Size and Forecast, By Drug Class
  - 6.3.5.2. Market Size and Forecast, By Indication
- 6.3.6. France Oncology-Cancer Drugs Market
  - 6.3.6.1. Market Size and Forecast, By Drug Class
  - 6.3.6.2. Market Size and Forecast, By Indication
- 6.3.7. UK Oncology-Cancer Drugs Market
  - 6.3.7.1. Market Size and Forecast, By Drug Class
  - 6.3.7.2. Market Size and Forecast, By Indication
- 6.3.8. Italy Oncology-Cancer Drugs Market
  - 6.3.8.1. Market Size and Forecast, By Drug Class
  - 6.3.8.2. Market Size and Forecast, By Indication
- 6.3.9. Spain Oncology-Cancer Drugs Market
  - 6.3.9.1. Market Size and Forecast, By Drug Class
  - 6.3.9.2. Market Size and Forecast, By Indication
- 6.3.10. Rest of Europe Oncology-Cancer Drugs Market
  - 6.3.10.1. Market Size and Forecast, By Drug Class
  - 6.3.10.2. Market Size and Forecast, By Indication
6.4. Asia-Pacific
- 6.4.1. Key Market Trends and Opportunities
- 6.4.2. Market Size and Forecast, By Drug Class
- 6.4.3. Market Size and Forecast, By Indication
- 6.4.4. Market Size and Forecast, By Country
- 6.4.5. China Oncology-Cancer Drugs Market
  - 6.4.5.1. Market Size and Forecast, By Drug Class
  - 6.4.5.2. Market Size and Forecast, By Indication
- 6.4.6. Japan Oncology-Cancer Drugs Market
  - 6.4.6.1. Market Size and Forecast, By Drug Class
  - 6.4.6.2. Market Size and Forecast, By Indication
- 6.4.7. India Oncology-Cancer Drugs Market
  - 6.4.7.1. Market Size and Forecast, By Drug Class
  - 6.4.7.2. Market Size and Forecast, By Indication
- 6.4.8. Australia Oncology-Cancer Drugs Market
  - 6.4.8.1. Market Size and Forecast, By Drug Class
  - 6.4.8.2. Market Size and Forecast, By Indication
- 6.4.9. South Korea Oncology-Cancer Drugs Market
  - 6.4.9.1. Market Size and Forecast, By Drug Class
  - 6.4.9.2. Market Size and Forecast, By Indication
- 6.4.10. Rest of Asia-Pacific Oncology-Cancer Drugs Market
  - 6.4.10.1. Market Size and Forecast, By Drug Class
  - 6.4.10.2. Market Size and Forecast, By Indication
6.5. LAMEA
- 6.5.1. Key Market Trends and Opportunities
- 6.5.2. Market Size and Forecast, By Drug Class
- 6.5.3. Market Size and Forecast, By Indication
- 6.5.4. Market Size and Forecast, By Country
- 6.5.5. Brazil Oncology-Cancer Drugs Market
  - 6.5.5.1. Market Size and Forecast, By Drug Class
  - 6.5.5.2. Market Size and Forecast, By Indication
- 6.5.6. South Africa Oncology-Cancer Drugs Market
  - 6.5.6.1. Market Size and Forecast, By Drug Class
  - 6.5.6.2. Market Size and Forecast, By Indication
- 6.5.7. Saudi Arabia Oncology-Cancer Drugs Market
  - 6.5.7.1. Market Size and Forecast, By Drug Class
  - 6.5.7.2. Market Size and Forecast, By Indication
- 6.5.8. Rest of LAMEA Oncology-Cancer Drugs Market
  - 6.5.8.1. Market Size and Forecast, By Drug Class
  - 6.5.8.2. Market Size and Forecast, By Indication

CHAPTER 7: COMPETITIVE LANDSCAPE

7.1. Introduction
7.2. Top Winning Strategies
7.3. Product Mapping of Top 10 Player
7.4. Competitive Dashboard
7.5. Competitive Heatmap
7.6. Top Player Positioning, 2023

CHAPTER 8: COMPANY PROFILES

8.1. AbbVie Inc.
- 8.1.1. Company Overview
- 8.1.2. Key Executives
- 8.1.3. Company Snapshot
- 8.1.4. Operating Business Segments
- 8.1.5. Product Portfolio
- 8.1.6. Business Performance
- 8.1.7. Key Strategic Moves and Developments
8.2. Amgen
- 8.2.1. Company Overview
- 8.2.2. Key Executives
- 8.2.3. Company Snapshot
- 8.2.4. Operating Business Segments
- 8.2.5. Product Portfolio
- 8.2.6. Business Performance
- 8.2.7. Key Strategic Moves and Developments
8.3. Astellas Pharma Inc.
- 8.3.1. Company Overview
- 8.3.2. Key Executives
- 8.3.3. Company Snapshot
- 8.3.4. Operating Business Segments
- 8.3.5. Product Portfolio
- 8.3.6. Business Performance
- 8.3.7. Key Strategic Moves and Developments
8.4. AstraZeneca Plc
- 8.4.1. Company Overview
- 8.4.2. Key Executives
- 8.4.3. Company Snapshot
- 8.4.4. Operating Business Segments
- 8.4.5. Product Portfolio
- 8.4.6. Business Performance
- 8.4.7. Key Strategic Moves and Developments
8.5. Bristol-Myers Squibb Company
- 8.5.1. Company Overview
- 8.5.2. Key Executives
- 8.5.3. Company Snapshot
- 8.5.4. Operating Business Segments
- 8.5.5. Product Portfolio
- 8.5.6. Business Performance
- 8.5.7. Key Strategic Moves and Developments
8.6. F. Hoffmann-La Roche Ltd.
- 8.6.1. Company Overview
- 8.6.2. Key Executives
- 8.6.3. Company Snapshot
- 8.6.4. Operating Business Segments
- 8.6.5. Product Portfolio
- 8.6.6. Business Performance
- 8.6.7. Key Strategic Moves and Developments
8.7. Johnson And Johnson
- 8.7.1. Company Overview
- 8.7.2. Key Executives
- 8.7.3. Company Snapshot
- 8.7.4. Operating Business Segments
- 8.7.5. Product Portfolio
- 8.7.6. Business Performance
- 8.7.7. Key Strategic Moves and Developments
8.8. Merck And Co., Inc.
- 8.8.1. Company Overview
- 8.8.2. Key Executives
- 8.8.3. Company Snapshot
- 8.8.4. Operating Business Segments
- 8.8.5. Product Portfolio
- 8.8.6. Business Performance
- 8.8.7. Key Strategic Moves and Developments
8.9. Novartis AG
- 8.9.1. Company Overview
- 8.9.2. Key Executives
- 8.9.3. Company Snapshot
- 8.9.4. Operating Business Segments
- 8.9.5. Product Portfolio
- 8.9.6. Business Performance
- 8.9.7. Key Strategic Moves and Developments
8.10. Pfizer Inc.
- 8.10.1. Company Overview
- 8.10.2. Key Executives
- 8.10.3. Company Snapshot
- 8.10.4. Operating Business Segments
- 8.10.5. Product Portfolio
- 8.10.6. Business Performance
- 8.10.7. Key Strategic Moves and Developments